BIRC6 inhibition in aged mouse and human blood stem cells: an abstract
In this abstract, a BIRC6-high blood stem cell subpopulation expanded in aged mice; blocking BIRC6 with antibody-conjugated lipid nanoparticles carrying antisense oligonucleotides reversed aging phenotypes in middle-aged mice and also worked in stem cells from middle-aged human donors. [1]
Automatic summary · not editorially reviewed
The key findings
A BIRC6-high blood stem cell subpopulation is markedly expanded in aged mice and reproduces hallmarks of stem cell aging. [1]
According to the abstract, cAMP from bone marrow Tregs activates PKA-CREB, activating Birc6 transcription and reducing apoptotic priming in aged stem cells. [1]
Targeted BIRC6 inhibition with antibody-conjugated lipid nanoparticles carrying antisense oligonucleotides reversed aging phenotypes in middle-aged mice and was also effective in stem cells from middle-aged human donors. [1]
The source at a glance
- Study type / format
- Preclinical study abstract (mouse experiments and human donor cell experiments)
- Population / context
- Aged and middle-aged mice, plus blood stem cells from middle-aged human donors, as described in the abstract.
- Summary based on
- Study abstract
- Original publication
- September 23, 2026
Aged mouse blood stem cells and bone marrow Tregs
The abstract describes immunosenescence as a hallmark of organismal aging, with declining immune function. Aging blood stem cells show aberrant expansion, myeloid-biased differentiation and impaired self-renewal, leading to hematopoietic-immune imbalance. The authors report that regulatory T cells in the bone marrow microenvironment help aged blood stem cells survive through a pathway they call previously uncharacterized. They identify a subpopulation with high expression of BIRC6, an apoptosis inhibitor; this subpopulation is markedly expanded in aged mice and reproduces hallmarks of stem cell aging.
Supporting source [1]
Treg-cAMP-PKA-CREB-BIRC6 pathway in aged stem cells
Mechanistically, the abstract states that cAMP from bone marrow Tregs activates the PKA-CREB pathway in blood stem cells, which activates Birc6 transcription. This reduces apoptotic priming in aged stem cells and thereby promotes hematopoietic-immune imbalance. The proposed chain is therefore a microenvironmental pathway the authors name Treg-cAMP-PKA-CREB-BIRC6. These are described mechanisms from the abstract, not established causal proof in humans.
Supporting source [1]
BIRC6 blockade in middle-aged mice and human donor cells
The abstract reports that targeted BIRC6 inhibition in blood stem cells, using antibody-conjugated lipid nanoparticles encapsulating antisense oligonucleotides, significantly reversed hematopoietic-immune aging phenotypes and ameliorated age-associated immune dysfunction in middle-aged mice. Treatment reportedly rebalanced immune cell production, reduced immunosenescence markers and enhanced vaccine responses in these mice. The strategy was also effective in blood stem cells from middle-aged human donors, which the authors call potential for clinical translation. These are abstract-level results; the full text was not reviewed.
Supporting source [1]
How to interpret this
This is an abstract; the full text was not reviewed. Design details, sample sizes, follow-up and statistical uncertainty are not reported here. Mouse and donor-cell results are preclinical and do not establish human lifespan or clinical benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Liao W, Shao F, Wang S, Wang Y, Chen X, Zhang Y, Zhang Z, Zai X, Yang Y, Yin Y, Wang Y, Zhang J, Wang J, Xu J. · europepmc.org · September 23, 2026